Cynata Therapeutics

Ross Macdonald, Ph.D., CEO
Melbourne, Australia
Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell (MSC) platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilises induced pluripotent stem cells (iPSCs) to produce MSCs through a proprietary process that is independent of donor limitations providing an “off-the-shelf” stem cell platform for therapeutic product manufacture. A successful world-first clinical trial in GvHD has been completed, meeting all safety and efficacy endpoints. The Company expects to commence three Phase II trials during 2020, in GvHD, osteoarthritis, and COVID-19. Cynata has a strategic partnership with Fujifilm, which is one of the Company’s larger shareholders.

By using this website you agree to accept our Privacy Policy and Terms & Conditions